The Company’s venture capital and other strategic investment performance has been excluded from non-GAAP results. GAAP earnings per share included a loss from the Company’s venture capital and other strategic investments of $0.03 per share in the first quarter of 2023, compared to a loss of $0.20 per share for the same period in 2022. First-quarter diluted earnings per share on a GAAP basis were $2.01, an increase of 11.0% from $1.81 for the first quarter of 2022. On a GAAP basis, first-quarter net income attributable to common shareholders was $103.1 million, an increase of 10.9% from $93.0 million for the same period in 2022. Excluding the effect of these items, organic revenue growth of 15.4% was driven by the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) business segments. The impact of foreign currency translation reduced reported revenue growth by 2.1%. For the quarter, revenue was $1.03 billion, an increase of 12.6% from $913.9 million in the first quarter of 2022.Īcquisitions contributed 1.8% to consolidated first-quarter revenue growth, and the divestiture of the Avian Vaccine business in December 2022 reduced reported revenue growth by 2.5%. (NYSE: CRL) today reported its results for the first quarter of 2023. WILMINGTON, Mass., May 11, 2023-( BUSINESS WIRE)-Charles River Laboratories International, Inc. – First-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.78 – – First-Quarter Revenue of $1.03 Billion –
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |